{"id":946126,"date":"2026-03-23T08:17:28","date_gmt":"2026-03-23T12:17:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-presents-new-data-from-its-ad-004-phase-iib-iii-trial-at-ad-pd-2026-conference-demonstrating-consistent-correlation-between-the-treatment-effect-of-oral-blarcamesine-and-preservat\/"},"modified":"2026-03-23T08:17:28","modified_gmt":"2026-03-23T12:17:28","slug":"anavex-life-sciences-presents-new-data-from-its-ad-004-phase-iib-iii-trial-at-ad-pd-2026-conference-demonstrating-consistent-correlation-between-the-treatment-effect-of-oral-blarcamesine-and-preservat","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-presents-new-data-from-its-ad-004-phase-iib-iii-trial-at-ad-pd-2026-conference-demonstrating-consistent-correlation-between-the-treatment-effect-of-oral-blarcamesine-and-preservat\/","title":{"rendered":"Anavex Life Sciences Presents New Data from its AD-004 Phase IIb\/III Trial at AD\/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer\u2019s Disease"},"content":{"rendered":"
\n

\n New data show brain-volume preservation correlates with patient outcomes<\/em>\n <\/p>\n

\n Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI<\/em>
\n
\n 1<\/em>
\n <\/sup>
\n control group after 144 weeks (33.1 months) of treatment<\/em>\n <\/p>\n

\n Oral presentation at the AD\/PD\u2122<\/em>
\n \u00a02026 Conference Symposium: \u2018Advances in AD treatment\u2019 highlights the convenience of oral blarcamesine for both patients and families<\/em>\n <\/p>\n

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced new data of blarcamesine was presented at the AD\/PD\u2122\u00a02026 Conference by Prof. Dr. Timo Grimmer, MD, and collaborators, titled, Advancing Alzheimer\u2019s Disease Care: Convenience for both Patients and Families with Oral Blarcamesine with Long-term Time Saved,<\/em> drawing from the ANAVEX\u00ae2-73-AD-004 (NCT03790709) Phase IIb\/III clinical program and its long-term open-label extension, ANAVEX\u00ae2-73-AD-EP-004 (NCT04314934).<\/p>\n

\u201cThe patient-friendly oral administration, the manageable side effects, and the clinical efficacy\u2014particularly in the genetically defined ABCLEAR32<\/sup> population\u2014make blarcamesine, in conjunction with the associated biomarker signal, a promising drug candidate for patients with early-stage Alzheimer\u2019s disease,\u201d said Prof. Dr Timo Grimmer, MD, member of the Anavex Scientific Advisory Board and National Coordinating Investigator for the blarcamesine Phase IIb\/III ANAVEX\u00ae2-73-AD-004 study. \u201cAlzheimer\u2019s disease is a devastating chronic disease that affects millions worldwide. We believe, these new results will contribute to the growing body of scientific data demonstrating the long-term beneficial effect of blarcamesine in early Alzheimer\u2019s disease.\u201d<\/p>\n

Data from the ANAVEX\u00ae2-73-AD-004 study also show that patients with wild-type (WT) SIGMAR1 and COL24A1 genes, the ABCLEAR32<\/sup> population, may experience substantially greater clinical and structural benefit from blarcamesine. This reinforces Anavex\u2019s precision medicine strategy, leveraging genomic and biomarker-based indicators to optimize therapeutic efficacy.3<\/sup><\/p>\n

A dedicated analysis of MRI biomarkers demonstrated a highly consistent correlation between slowing of atrophy and improvements across primary and secondary clinical endpoints, including:<\/p>\n